[Bone marrow re-transplantation following a busulfan and cyclophosphamide regimen].
A 36-year-old man was diagnosed as having RAEB in 1986, and required blood transfusion regularly because of severe anemia. He received the first bone marrow transplantation following total-body irradiation and etoposide infusion in October 1987. He was found to be relapsed into RAEB on 106th day after BMT. And the second BMT was planned. According to the conditioning regimen of Tutschka, et al, we administrated busulfan and cyclophosphamide before re-transplantation. On 26th day after BMT, the WBC count exceeded 1,000/microliters and anemia was improved, while thrombocytopenia persisted until 50th day. Normal hematopoiesis in the bone marrow was confirmed on the 29th day. No severe side effect except for a little fevering and bleeding was found during the clinical course. Unfortunately he died of pneumonia following graft versus host disease on the 166th day after re-BMT. This new conditioning regimen is considered to be a choice for the high risk patients on re-transplantation.
Hirasawa
A
A
Second Department of Internal Medicine, School of Medicine, Chiba University.
Hiruma
K
K
Wakita
H
H
Endo
N
N
Takabayashi
K
K
Oh
H
H
Yoshida
S
S
Aotsuka
N
N
Asai
T
T
Igarashi
T
T
D000328:Adult; D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy / Q000601:surgery*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000379:methods; D002066:Busulfan / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D011300:Preoperative Care; D012086:Reoperation
D003520:Cyclophosphamide; D002066:Busulfan